ECSP088262A - Proteínas de fusión de albúmina - Google Patents

Proteínas de fusión de albúmina

Info

Publication number
ECSP088262A
ECSP088262A EC2008008262A ECSP088262A ECSP088262A EC SP088262 A ECSP088262 A EC SP088262A EC 2008008262 A EC2008008262 A EC 2008008262A EC SP088262 A ECSP088262 A EC SP088262A EC SP088262 A ECSP088262 A EC SP088262A
Authority
EC
Ecuador
Prior art keywords
albumin fusion
fusion proteins
vectors
host cells
methods
Prior art date
Application number
EC2008008262A
Other languages
English (en)
Inventor
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of ECSP088262A publication Critical patent/ECSP088262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende proteínas de fusión de albúmina. Las moléculas de ácido nucleicoque codifican las proteínas de fusión de albúmina de la invención también están comprendidas en la invención, así como los vectores que contienen estos ácidos nucleicos, las células hospederas transformadas con estos vectores de ácidos nucleicos, y los métodos de hacer las proteínas de fusión de albúmina de la invención y de usar estos ácidos nucleicos, vectores, y/o células hospederas. Adicionalmente, la presente invención incluye composiciones farmacéuticas que comprenden las proteínas de fusión de albúmina y los métodos de tratamiento, prevención o mejoramiento de las enfermedades, trastornos o condiciones utilizando las proteínas de fusión de albúmina de la invención.
EC2008008262A 2005-08-12 2008-03-12 Proteínas de fusión de albúmina ECSP088262A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
ECSP088262A true ECSP088262A (es) 2008-05-30

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008262A ECSP088262A (es) 2005-08-12 2008-03-12 Proteínas de fusión de albúmina

Country Status (13)

Country Link
EP (1) EP1924596A4 (es)
JP (1) JP2009504157A (es)
KR (1) KR20080071119A (es)
AU (1) AU2006280312A1 (es)
BR (1) BRPI0614761A2 (es)
CA (1) CA2618476A1 (es)
EC (1) ECSP088262A (es)
IL (1) IL189246A0 (es)
MA (1) MA29836B1 (es)
MX (1) MX2008001865A (es)
NO (1) NO20081233L (es)
TN (1) TNSN08064A1 (es)
WO (1) WO2007021494A2 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0712383A2 (pt) * 2006-06-07 2012-07-10 Human Genome Sciences Inc proteìnas de fusão da albumina
AU2007294805A1 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
BR112012009450A2 (pt) * 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
EP2682128B1 (en) * 2011-02-28 2017-11-08 National Cerebral and Cardiovascular Center Atrial natriuretic peptide or brain natriuretic peptide for use in preventing metastasis
AU2012251583B2 (en) 2011-05-05 2017-06-08 Albumedix Ltd. Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
SG11202007114VA (en) 2018-02-01 2020-08-28 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
AU2019393880A1 (en) 2018-12-06 2021-07-15 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor IX
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
WO2022030580A1 (ja) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
EP4603587A1 (en) * 2022-10-11 2025-08-20 JCR Pharmaceuticals Co., Ltd. Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425738T3 (es) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
KR20080071119A (ko) 2008-08-01
CA2618476A1 (en) 2007-02-22
JP2009504157A (ja) 2009-02-05
EP1924596A4 (en) 2009-07-29
NO20081233L (no) 2008-05-09
MX2008001865A (es) 2008-04-15
AU2006280312A1 (en) 2007-02-22
IL189246A0 (en) 2008-08-07
WO2007021494A3 (en) 2007-07-26
WO2007021494A2 (en) 2007-02-22
BRPI0614761A2 (pt) 2009-05-19
TNSN08064A1 (en) 2009-07-14
EP1924596A2 (en) 2008-05-28
MA29836B1 (fr) 2008-10-03

Similar Documents

Publication Publication Date Title
ECSP088262A (es) Proteínas de fusión de albúmina
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007146038A3 (en) Albumin fusion proteins
BRPI0507026A (pt) proteìnas de fusão de albumina
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
UY29344A1 (es) Anticuerpos antiamiloides humanizados
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
CR8978A (es) Proteinas de fusion de dominio de union
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
WO2003030821A3 (en) Albumin fusion proteins
ECSP077240A (es) Variantes mejoradas de la aprotinina
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
ATE539086T1 (de) Interleukin-11-fusionsproteine
UY29544A1 (es) Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung